ReviewMetabolism open2024
Paraneoplastic hypoglycemia: An overview for optimal clinical guidance.
Review in Metabolism open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management.Metabolism open · 2026Review
- Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark.Reviews in endocrine & metabolic disorders · 2026Review
- Acromegalic features and hypoglycemia: Doege-Potter syndrome.Caspian journal of internal medicine · 2026Article
- Non-islet cell tumor hypoglycemia (NICTH) as a rare paraneoplastic syndrome in high-grade serous ovarian carcinoma: A case report and review of the literature.Gynecologic oncology reports · 2025Article
- Management of Non-Islet Cell Tumor Hypoglycemia Induced by Adrenal Cortical Carcinoma.JCEM case reports · 2025Article
- Non-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD).Cardiovascular diabetology. Endocrinology reports · 2025Review
- An Unexpected Manifestation of Non-islet Cell Tumor Hypoglycemia in Pancreatic Ductal Adenocarcinoma.Cureus · 2025Article
- Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review).Molecular and clinical oncology · 2025Review
- Pancreatic Neuroendocrine Tumors-Diagnostic Pitfalls of Non-Diabetic Severe Hypoglycemia: Literature Review and Case Report.Diagnostics (Basel, Switzerland) · 2025Article
- Resolution of Refractory Nonislet Cell Tumor Hypoglycemia Following Resection of an Abdominal Solitary Fibrous Tumor.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic hypoglycemia, also known as non-islet cell tumor hypoglycemia (NICTH), is a rare but critical condition occurring in patients with different types of malignancy. This condition is commonly linked to tumors producing insulin-like growth (IGF) factors, particularly IGF-2 and its precursors, which disrupt glucose homeostasis and lead to excessive glucose consumption. The diagnosis typically involves documenting symptomatic hypoglycemia and ruling out other potential causes. Essential diagnostic tools include imaging studies and laboratory tests, specifically measuring IGF-2 levels and the IGF-2:IGF-1 ratio. Treatment strategies for NICTH are multifaceted and may include surgical resection of the tumor if feasible, pharmacological interventions such as corticosteroids to suppress IGF-2 production, or supportive measures to manage acute hypoglycemic episodes. Novel therapeutic approaches targeting IGF-2, such as monoclonal antibodies or siRNA, are also being explored and hold promise for future treatment options. This review aims to enhance understanding of paraneoplastic hypoglycemia, focusing on its pathogenesis and diagnosis, to guide optimal medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.